pembrolizumab,nemvaleukin
alkermes,merck
['ovarian', 'artistry-7', 'alkermes']
a large unmet need remains for more treatment options for patients living with platinum-resistant ovarian cancer. this need drives the ongoing research in our artistry-7 clinical trial. learn more about our work at #asco22.
Developing innovative medicines to help address pressing public health challenges – #mentalillness, #addiction & #cancer. Guidelines: https://t.co/oR0kiGaovc